Objective: This study aimed to assess the effects of multi-donor fecal microbiota transplantation (FMT) capsules combined with thalidomide on hormone-dependent ulcerative colitis (UC).
Methods: A total of 59 patients with steroid-dependent UC treated at the Gastroenterology Department of the First Affiliated Hospital of Xinxiang Medical University between January 2017 and January 2019 were enrolled in this study. Using a random number table, the patients were divided into two groups: a group treated with FMT capsules (the FMT group) and a group treated with FMT capsules and thalidomide (the FMT+S group). Multi-donor FMT capsules were prepared, and all subjects and stool donors followed the FMT pathway for FMT transplantation. Each patient's Mayo score, C-reactive protein (CRP) level, and level of fecal calprotectin before FMT treatment and at week 1 and week 13 after treatment were recorded. All patients were followed up for 15 weeks.
Results: A total of 56.7% of the patients (34/59) achieved a therapeutic response at the end of the research period. Compared with the FMT group, the FMT+S group had better clinical benefit (P < 0.05). In the comparison of efficacy at week 1 and week 13 after treatment, the Mayo scores, calprotectin levels, and CRP indexes in the FMT+S group were better than those in the FMT group (P < 0.05). There were no serious adverse events in the treatment process or during follow-up.
Conclusion: A combination of FMT capsules and thalidomide provides a treatment choice for patients with hormone-dependent UC, and it can be used as an adjuvant therapy. However, large-scale, multi-center, and prospective trials are required to further verify the reliability of this treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784385 | PMC |
| http://dx.doi.org/10.2147/IDR.S385485 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fecal Microbiota Transplantation in Children with Autism.
Neuropsychiatr Dis Treat
December 2024
Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Purpose: This research aimed to explore the clinical efficacy of fecal microbiota transplantation (FMT) in treating children with autism spectrum disorder (ASD).
Methods: In this single-arm prospective study, every participant received FMT therapy, followed by an 8-week follow-up. Children unable to swallow lyophilized capsules (Caps) received fecal solution through transendoscopic enteral tube (TET) or nasal jejunal tube (NJT) approaches.
Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure of FMT Alone in the Treatment of Recurrent C. difficile Infection.
J Clin Gastroenterol
November 2024
Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, MN.
Article Synopsis
- The study aimed to assess the effectiveness of adding bezlotoxumab to repeat fecal microbiota transplantation (FMT) for patients with recurrent Clostridioides difficile infections after a previous unsuccessful FMT.
- It was found that combining bezlotoxumab with a second FMT significantly increased the cure rate from 48% to 89%.
- The research highlights the importance of understanding how bezlotoxumab and FMT work together and suggests that similar strategies could apply to other treatments for preventing C. difficile infection recurrence.
Development and evaluation of innovative enteric-coated capsules for colon-specific delivery of hydrophilic biomaterials.
Int J Pharm
January 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno 612 00, Czech Republic.
Objective: This research aims to design and evaluate an enteric-coated hard capsule dosage form for targeted delivery of biological materials, such as FMT (fecal microbiota transplant) or live microbes, to the distal parts of the GIT. The capsules are designed to be internally protected against destruction by hydrophilic filling during passage through the digestive tract.
Methods: Hard gelatin capsules and DRcapscapsules based on HPMC and gellan were used to encapsulate a hydrophilic body temperature-liquefying gelatin hydrogel with caffeine or insoluble iron oxide mixture.
Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease.
Am J Gastroenterol
November 2024
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Article Synopsis
- Fecal microbiota transplantation (FMT) was evaluated for its ability to induce remission in Crohn's disease (CD) in a double-blind study, marking the first investigation of its kind.
- The study involved 21 patients receiving FMT and 13 receiving a placebo, and was terminated early due to futility, showing no significant difference in remission rates between groups at week 8.
- While FMT did not improve clinical outcomes, both groups reported improvements in health-related quality of life; future research may explore alternative strategies to boost treatment efficacy.
Fecal microbiota transplantation alters the proteomic landscape of inflammation in HIV: identifying bacterial drivers.
Microbiome
October 2024
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS and Universidad de Alcalá, Carretera de Colmenar Viejo, Km 9.100, 28034, Madrid, Spain.
Background: Despite effective antiretroviral therapy, people with HIV (PWH) experience persistent systemic inflammation and increased morbidity and mortality. Modulating the gut microbiome through fecal microbiota transplantation (FMT) represents a novel therapeutic strategy. We aimed to evaluate proteomic changes in inflammatory pathways following repeated, low-dose FMT versus placebo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!